Article
Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy.
Cell death and differentiation - 1 Apr 2003
Sturm I, Bosanquet A G, Hermann S, Güner D, Dörken B, Daniel P T
Abstract excerpt
Inactivation of p53 has been shown to correlate with poor prognosis and drug resistance in malignant tumors. Nevertheless, few reports have directly shown such effects in primary tumor cells. Here, we investigated the p53 mutational status in 138 B-CLL samples and compared these findings with drug and gamma-irradiation sensitivity profiles. p53 mutations resulted not only in a shorter survival but, notably also...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.